DelveInsight's "Minimal Residual Disease Market Insights, Epidemiology, and Market Forecast 2030" reports deliver an in-depth understanding of the disease, historical and forecasted epidemiology, the pipeline insight as well as the Minimal Residual Disease market size and shares analysis in the seven major markets (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
The report also covers emerging drugs, current treatment practices, Minimal Residual Disease market shares of the individual therapies, a detailed current Minimal Residual Disease treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the market.
Minimal Residual Disease Market Key Facts
- As per the study by Pigneux et al. 2018, large prospective multicenter studies have found that 33–47% of patients have MRD after induction therapy. These studies have shown a strong association between the presence of MRD after front-line therapy and poor long-term outcomes, including an increased risk of relapse and shorter relapse-free, disease-free, and overall survival.
- According to the study by Moritz et al. 2019, in a study with venetoclax, among MRD-positive patients 23% showed intermediate (≥10−4 to <10−2) MRD levels and 51% had high MRD (≥10−2).
- As per the study by Bene and Kaeda 2009, in a study on patients with Chronic Lymphocytic Leukemia (CLL), the results showed that 21% of the patients assessed had undetectable MRD, with a median time of progression of 44 months compared with 27 months with detectable CLL cells.
Minimal Residual Disease Market Analysis
Minimal Residual Disease (MRD) Market Size is expected to increase during the study period owing to the increasing prevalent population of Minimal Residual Disease (MRD) patients in the 7MM. Extensive research and development activities of pharmaceutical companies, along with the expected launch of approved therapies, will also fuel the growth of the market.
The Minimal Residual Disease market analysis section of the report helps to understand the current and forecasted Minimal Residual Disease market trends and growth by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers. The report gives complete detail of Minimal Residual Disease market size and shares of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Minimal Residual Disease Epidemiology Forecast
The Minimal Residual Disease epidemiology section covers insights about historical and current Minimal Residual Disease patient pool and forecasted trends for every seven major countries (i.e., the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan. It helps to recognize the causes of current and forecasted Minimal Residual Disease Epidemiology trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends, along with assumptions undertaken.
Minimal Residual Disease Epidemiology Segmentation
- Total Prevalent cases of Minimal Residual Disease
- Cases of Minimal Residual Disease by Cause
- Severity-specific cases of Minimal Residual Disease
- Diagnosed Cases of Minimal Residual Disease
To eradicate relapses and provide better therapeutic options in cancers many trials are going on. Few drugs in the late phase of development are expected to enter the market by 2030. All of these therapies target different mechanisms and are expected to provide better treatment for MRD patients.
Key Companies in the Minimal Residual Disease Market include Amgen, Pfizer, Novartis, GlaxoSmithKline, Janssen Pharmaceuticals, and many others. Minimal Residual Disease Therapies covered in the report include Ofatumumab, Daratumumab + Lenalidomide, Midostaurin + Combination, Gemtuzumab ozogamicin, and many more.
For more details, visit: Minimal Residual Disease Market Trends